Safety and Immunogenicity of Heterologous Boost Immunisation With an Aerosolized Ad5-nCoV After Two-Dose Priming With an Inactivated SARS-CoV-2 Vaccine CoronaVac in Adults: A Randomised, Open-Label, Parallel-Control Trial
Jingxin Li(Beijing Tongren Hospital), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Shipo Wu(Academy of Military Medical Sciences), Weixue Si, Rong Tang(Jiangsu Provincial Center for Disease Control and Prevention), Jin Zhong(Chinese Academy of Sciences), Jin-Bo Gou, Fengjuan Shi(Jiangsu Provincial Center for Disease Control and Prevention), Baoying Huang(National Institute for Viral Disease Control and Prevention), Lunbiao Cui(Jiangsu Provincial Center for Disease Control and Prevention), Lihua Hou(Academy of Military Medical Sciences), Tao Zhu, Zhuo-Pei Li(Nanjing Medical University), Xue Wang(Ningxia Hui Autonomous Region Peoples Hospital), Yin Chen(Southern Medical University), Jingxian Liu(Jiangsu Provincial Center for Disease Control and Prevention), Xiaoqin Chen(North Sichuan Medical University), Xiaolong Zhao(China Pharmaceutical University), Xiaoyin Zhang(Southeast University), Xiling Guo(Jiangsu Provincial Center for Disease Control and Prevention), Wei Chen(Academy of Military Medical Sciences), Wenjie Tan(Shandong University), Xiaoyu Xu, Hongxing Pan(Jiangsu Provincial Center for Disease Control and Prevention)
Cited by 1
Related Papers
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k
Co-infection with respiratory pathogens among COVID-2019 cases
|Virus Research|2020|637
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China
|The Journal of Infectious Diseases|2020|391
A Family Cluster of Infections by a Newly Recognized Bunyavirus in Eastern China, 2007: Further Evidence of Person-to-Person Transmission
|Clinical Infectious Diseases|2011|268
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
|Signal Transduction and Targeted Therapy|2021|204